News
ALVO
3.670
+3.38%
0.120
Alvotech Clears Key FDA Inspection at Reykjavik Plant, Paving Way for 2026 BLA Resubmissions
TipRanks · 2d ago
Alvotech Completes FDA Surveillance Inspection At Reykjavik Facility, Prepares BLA Resubmissions
NASDAQ · 2d ago
Alvotech shares rise as FDA completes Reykjavik facility inspection
Seeking Alpha · 3d ago
Weekly Report: what happened at ALVO last week (0504-0508)?
Weekly Report · 3d ago
Alvotech announces cGMP surveillance inspection of Reykjavik facility
TipRanks · 3d ago
Alvotech says FDA completes inspection of Reykjavik manufacturing plant
PUBT · 3d ago
ALVOTECH SA - EXPECTS FDA APPROVAL FOR RELEVANT BLAS IN 2026
Reuters · 3d ago
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
Barchart · 3d ago
Alvotech Earnings Call Balances Risk and Growth
TipRanks · 5d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 05/06 21:03
Earnings Scheduled For May 6, 2026
Benzinga · 05/06 21:03
Alvotech reports Q1 results
Seeking Alpha · 05/06 20:58
ALVOTECH Q1 REVENUE $105.9 MILLION
Reuters · 05/06 20:54
ALVOTECH OUTLOOK FY REVENUE $650 MILLION - $700 MILLION
Reuters · 05/06 20:54
ALVOTECH Q1 ADJ EBITDA $24.4 MILLION
Reuters · 05/06 20:54
Alvotech Q1 Sales $105.900M Miss $140.847M Estimate
Benzinga · 05/06 20:34
Alvotech Announces General Counsel Transition After Six-Year Tenure
TipRanks · 05/04 12:57
Alvotech general counsel Tanya Zharov steps down after six years
PUBT · 05/04 12:35
Weekly Report: what happened at ALVO last week (0427-0501)?
Weekly Report · 05/04 09:52
More
Webull provides a variety of real-time ALVO stock news. You can receive the latest news about Alvotech through multiple platforms. This information may help you make smarter investment decisions.
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.